← Leaderboards
Senad Divanovic
Cincinnati Childrens Hosp Med Ctr
$5,895,252
Attributed
$6,385,445
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $968.6K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,385,445 · 5
By mechanism
R01$4,742,989 · 1
R21$1,642,456 · 4
Top collaborators
- Ian Paul Lewkowich5 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Ian Paul Lewkowich$6,739,276
- Claire A Chougnet$14,082,863
- Angela Marie Cannata$125,029
- Erik Bradford Hysinger$788,438
- Nehal A Parikh$9,625,203
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionInflammationPathogenesisExhibitsCytokineInflammatoryMetabolicObesityImmune ResponseCellsDietCell TypePathway InteractionsInterleukin-17ImmuneLiteratureInsightCharacteristicsPreventiveAntibodiesHepatocellular DamageHepatocyteHepaticLiver
Grant awards (21)
Contribution of adipose tissue immune cells to Influenza pathogenesis$240,750
R21 · FY2025 · AI · contact PI
Role of Innate Lymphocytes in Obese Asthma$194,606
R21 · FY2025 · AI
Role of Innate Lymphocytes in Obese Asthma$240,750
R21 · FY2024 · AI
Immunopathogenesis of non-alcoholic fatty liver disease$554,436
R01 · FY2023 · DK · contact PI
Immunopathogenesis of non-alcoholic fatty liver disease$554,436
R01 · FY2022 · DK · contact PI
Immunopathogenesis of non-alcoholic fatty liver disease$554,436
R01 · FY2021 · DK · contact PI
Obesity, Metabolic Syndrome and Asthma$198,750
R21 · FY2021 · AI
Immunopathogenesis of non-alcoholic fatty liver disease$67,836
R01 · FY2021 · DK · contact PI
Immunopathogenesis of non-alcoholic fatty liver disease$554,436
R01 · FY2020 · DK · contact PI
Obesity, Metabolic Syndrome and Asthma$238,500
R21 · FY2020 · AI
Obesity, Metabolic Syndrome and Asthma$107,780
R21 · FY2020 · AI
Immunopathogenesis of non-alcoholic fatty liver disease$67,836
R01 · FY2020 · DK · contact PI
Immunopathogenesis of non-alcoholic fatty liver disease$550,978
R01 · FY2019 · DK · contact PI
Immunopathogenesis of Non-alcoholic Fatty Liver Disease$332,775
R01 · FY2017 · DK · contact PI
Immunopathogenesis of Non-alcoholic Fatty Liver Disease$332,775
R01 · FY2016 · DK · contact PI
Immunopathogenesis of Non-alcoholic Fatty Liver Disease$420,135
R01 · FY2015 · DK · contact PI
Immunopathogenesis of Non-alcoholic Fatty Liver Disease$332,775
R01 · FY2014 · DK · contact PI
Immunopathogenesis of Non-alcoholic Fatty Liver Disease$87,360
R01 · FY2014 · DK · contact PI
Immunopathogenesis of Non-alcoholic Fatty Liver Disease$332,775
R01 · FY2013 · DK · contact PI
Better mouse models of disease: Humanizing experimental atherosclerosis$178,834
R21 · FY2013 · HL · contact PI
Better mouse models of disease: Humanizing experimental atherosclerosis$242,486
R21 · FY2012 · HL · contact PI